Proteins and Peptides

04 Dec 2017 La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC‑401 in Patients with Beta Thalassemia
04 Dec 2017 Sanofi's Toujeo® met main objective in head-to-head study versus insulin degludec
29 Nov 2017 Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
29 Nov 2017 Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)
27 Nov 2017 Pharming Submits Supplemental Biologics License Application to FDA for RUCONEST® for Prophylaxis of Hereditary Angioedema Attacks
17 Nov 2017 Medicenna Presents Updates on Phase 2b Clinical Trial of MDNA55 at the Annual Meeting of the Society of Neuro-Oncology
16 Nov 2017 Sobi™ - First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Still's Disease
15 Nov 2017 FDA approves treatment for rare genetic enzyme disorder
14 Nov 2017 Recruitment completed in trial to evaluate the optimal dosing frequency for Zealand's long-acting GLP-2 analog glepaglutide
12 Nov 2017 First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017
10 Nov 2017 New Data on FORTEO® (teriparatide [rDNA origin] injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis
09 Nov 2017 Novaliq Announces First Patient Randomized in Its ESSENCE Phase 2b/3 Trial of CyclASol® for the Treatment of the Signs and Symptoms of Dry Eye Disease
09 Nov 2017 Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200
08 Nov 2017 Positive Preclinical Data for ALKS 4230 Presented at Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
08 Nov 2017 Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting
07 Nov 2017 UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder
06 Nov 2017 Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification
02 Nov 2017 Biomarck Announces First Patients Treated in Phase 2 Clinical Trial of BIO-11006 for Acute Respiratory Distress Syndrome (ARDS)
01 Nov 2017 Kamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients
31 Oct 2017 NeoMatrix Therapeutics Enters Clinical Stage as Investigational New Drug Application for NMT-cP12 Goes Into Effect
31 Oct 2017 Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 1 Study of Peptelligence™-Engineered Oral CR845 in Non-Hemodialysis Chronic Kidney Disease Patients
31 Oct 2017 Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
30 Oct 2017 Bayer Announces BAY94-9027 Biologics License Application Accepted by U.S. Food & Drug Administration
27 Oct 2017 Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
25 Oct 2017 The first patient enrolled in the ReITIrate study evaluating immune tolerance induction with Elocta

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing